THE geopolitical tensions in the Middle East have understandably prompted national discussions regarding the resilience of our essential supply chains. During such periods of global volatility, ensuring the uninterrupted supply of critical medicines is a matter of paramount national interest.
First, the public can be assured that the current supply of pharmaceutical products from local manufacturers is stable, and the industry is proactively building up resilience against any major or unforeseen disruptions.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
